Review



hotspot panel sequenom massarray  (Sequenom)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Sequenom hotspot panel sequenom massarray
    Hotspot Panel Sequenom Massarray, supplied by Sequenom, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/hotspot+panel+sequenom+massarray/hotspot+panel+sequenom+massarray/pm33493663-79-161-163
    Average 90 stars, based on 1 article reviews
    hotspot panel sequenom massarray - by Bioz Stars, 2026-10
    90/100 stars

    Images

    Related Articles

    Biomarker Discovery:

    Article Title: Real-World Utilization of Biomarker Testing for Patients with Advanced Non-Small Cell Lung Cancer in a Tertiary Referral Center and Referring Hospitals.
    Article Snippet: In some patients, the same test was Table 2 Descriptives of Biomarker Tests Conducted at the CCC Biomarker Test technique or platform Absolute frequency Unique patients tested, n (%) Turnaround time, median (IQR), days Cost, EUR Cost, USD MET exon 14 deletion RT-PCR 85 78 (77.2) 8.1 (4.1) 275.24 330.43 EGFR, HER2 Multiplex fragment analysis 77 73 (72.3) 8.3 (5.0) 436.26* 523.73 PD-L1 IHC 70 70 (69.3) NA 93.74 112.53 Assay TSACP MiSeq (Illumina, San Diego, CA)y 44 41 (40.6) 11.8 (3.8) 258.96 310.88 Path version 2Dz 23 17 (16.8) 86.9 (100) 993.67x 1192.90 Archer FusionPlex MiSeq (Illumina){ 2 2 (2.0) 9.1 (9.1) 993.67x 1192.90 Total 69 54 (53.5) 12.8 (9.2) 417.57 501.23 ALK IHC 54 54 (53.5) NA 101.88 122.31 FISH 5 3 (3.0) 7.7 (4.8) 134.48 161.44 Total 59 55 (54.5) 7.7 (4.8) 102.16 122.64 ROS1 IHC 50 50 (49.5) NA 101.88 122.31 FISH 8 6 (5.9) 9.9 (3.1) 134.48 161.44 Total 58 51 (50.5) 9.9 (3.1) 102.69 123.28 Hotspot panel Sequenom MassARRAY 51 46 (45.5) 7.8 (3.2) 436.26* 523.73 MET FISH 33 29 (28.7) 9.1 (4.8) 134.48 161.44 DISH 8 8 (7.9) NA 436.26* 523.73 IHC 1 1 (1.0) NA 97.81 117.42 Total 42 34 (33.7) 9.1 (4.8) 151.18 181.49 NTRK IHC 41 41 (40.6) NA 97.81 117.42 RET FISH 38 34 (33.7) 10.9 (7.4) 134.48 161.44 HER2 IHC 12 12 (11.9) NA 97.81 117.42 DISH 7 7 (6.9) NA 436.26* 523.73 Sanger sequencing 3 2 (2.0) 10.3 (6.4) 71.19 85.46 FISH 1 1 (1.0) 10.9 134.48 161.44 Total 23 14 (13.9) 10.6 (3.6) 178.51 214.30 FGR1 FISH 5 5 (5.0) 17.8 (4.6) 134.48 161.44 EGFR FISH 3 2 (2.0) 9.2 (5.9) 134.48 161.44 Sanger sequencing 2 1 (1.0) NA 71.19 85.46 Total 5 3 (3.0) 9.2 (5.9) 115.01 138.07 EGFR T790M HRM sequencing 4 4 (4.0) 5.9 (2.0) 97.62 117.19 NRAS Sanger sequencing 1 1 (1.0) 55 (0.0) 60.58 72.73 HRM sequencing 1 1 (1.0 7.8 (0.0) 74.56 89.51 Total 2 2 (2.0) 31.4 (23.6) 67.57 81.12 NRAS exon 4 Sanger sequencing 2 2 (2.0) 9.2 (2.4) 60.58 72.73 TP53 Sanger sequencing 2 2 (2.0) 9.2 (0.0) 65.40 78.51 KRAS HRM sequencing 1 1 (1.0) 8.2 (0.0) 97.62 117.19 Sanger sequencing 1 1 (1.0) 6.8 (0.0) 67.33 80.83 Total 2 2 (2.0) 7.5 (0.7) 82.47 99.01 The table includes only biomarkers that were tested more than once.

    Countercurrent Chromatography:

    Article Title: Real-World Utilization of Biomarker Testing for Patients with Advanced Non-Small Cell Lung Cancer in a Tertiary Referral Center and Referring Hospitals.
    Article Snippet: In some patients, the same test was Table 2 Descriptives of Biomarker Tests Conducted at the CCC Biomarker Test technique or platform Absolute frequency Unique patients tested, n (%) Turnaround time, median (IQR), days Cost, EUR Cost, USD MET exon 14 deletion RT-PCR 85 78 (77.2) 8.1 (4.1) 275.24 330.43 EGFR, HER2 Multiplex fragment analysis 77 73 (72.3) 8.3 (5.0) 436.26* 523.73 PD-L1 IHC 70 70 (69.3) NA 93.74 112.53 Assay TSACP MiSeq (Illumina, San Diego, CA)y 44 41 (40.6) 11.8 (3.8) 258.96 310.88 Path version 2Dz 23 17 (16.8) 86.9 (100) 993.67x 1192.90 Archer FusionPlex MiSeq (Illumina){ 2 2 (2.0) 9.1 (9.1) 993.67x 1192.90 Total 69 54 (53.5) 12.8 (9.2) 417.57 501.23 ALK IHC 54 54 (53.5) NA 101.88 122.31 FISH 5 3 (3.0) 7.7 (4.8) 134.48 161.44 Total 59 55 (54.5) 7.7 (4.8) 102.16 122.64 ROS1 IHC 50 50 (49.5) NA 101.88 122.31 FISH 8 6 (5.9) 9.9 (3.1) 134.48 161.44 Total 58 51 (50.5) 9.9 (3.1) 102.69 123.28 Hotspot panel Sequenom MassARRAY 51 46 (45.5) 7.8 (3.2) 436.26* 523.73 MET FISH 33 29 (28.7) 9.1 (4.8) 134.48 161.44 DISH 8 8 (7.9) NA 436.26* 523.73 IHC 1 1 (1.0) NA 97.81 117.42 Total 42 34 (33.7) 9.1 (4.8) 151.18 181.49 NTRK IHC 41 41 (40.6) NA 97.81 117.42 RET FISH 38 34 (33.7) 10.9 (7.4) 134.48 161.44 HER2 IHC 12 12 (11.9) NA 97.81 117.42 DISH 7 7 (6.9) NA 436.26* 523.73 Sanger sequencing 3 2 (2.0) 10.3 (6.4) 71.19 85.46 FISH 1 1 (1.0) 10.9 134.48 161.44 Total 23 14 (13.9) 10.6 (3.6) 178.51 214.30 FGR1 FISH 5 5 (5.0) 17.8 (4.6) 134.48 161.44 EGFR FISH 3 2 (2.0) 9.2 (5.9) 134.48 161.44 Sanger sequencing 2 1 (1.0) NA 71.19 85.46 Total 5 3 (3.0) 9.2 (5.9) 115.01 138.07 EGFR T790M HRM sequencing 4 4 (4.0) 5.9 (2.0) 97.62 117.19 NRAS Sanger sequencing 1 1 (1.0) 55 (0.0) 60.58 72.73 HRM sequencing 1 1 (1.0 7.8 (0.0) 74.56 89.51 Total 2 2 (2.0) 31.4 (23.6) 67.57 81.12 NRAS exon 4 Sanger sequencing 2 2 (2.0) 9.2 (2.4) 60.58 72.73 TP53 Sanger sequencing 2 2 (2.0) 9.2 (0.0) 65.40 78.51 KRAS HRM sequencing 1 1 (1.0) 8.2 (0.0) 97.62 117.19 Sanger sequencing 1 1 (1.0) 6.8 (0.0) 67.33 80.83 Total 2 2 (2.0) 7.5 (0.7) 82.47 99.01 The table includes only biomarkers that were tested more than once.

    Reverse Transcription Polymerase Chain Reaction:

    Article Title: Real-World Utilization of Biomarker Testing for Patients with Advanced Non-Small Cell Lung Cancer in a Tertiary Referral Center and Referring Hospitals.
    Article Snippet: In some patients, the same test was Table 2 Descriptives of Biomarker Tests Conducted at the CCC Biomarker Test technique or platform Absolute frequency Unique patients tested, n (%) Turnaround time, median (IQR), days Cost, EUR Cost, USD MET exon 14 deletion RT-PCR 85 78 (77.2) 8.1 (4.1) 275.24 330.43 EGFR, HER2 Multiplex fragment analysis 77 73 (72.3) 8.3 (5.0) 436.26* 523.73 PD-L1 IHC 70 70 (69.3) NA 93.74 112.53 Assay TSACP MiSeq (Illumina, San Diego, CA)y 44 41 (40.6) 11.8 (3.8) 258.96 310.88 Path version 2Dz 23 17 (16.8) 86.9 (100) 993.67x 1192.90 Archer FusionPlex MiSeq (Illumina){ 2 2 (2.0) 9.1 (9.1) 993.67x 1192.90 Total 69 54 (53.5) 12.8 (9.2) 417.57 501.23 ALK IHC 54 54 (53.5) NA 101.88 122.31 FISH 5 3 (3.0) 7.7 (4.8) 134.48 161.44 Total 59 55 (54.5) 7.7 (4.8) 102.16 122.64 ROS1 IHC 50 50 (49.5) NA 101.88 122.31 FISH 8 6 (5.9) 9.9 (3.1) 134.48 161.44 Total 58 51 (50.5) 9.9 (3.1) 102.69 123.28 Hotspot panel Sequenom MassARRAY 51 46 (45.5) 7.8 (3.2) 436.26* 523.73 MET FISH 33 29 (28.7) 9.1 (4.8) 134.48 161.44 DISH 8 8 (7.9) NA 436.26* 523.73 IHC 1 1 (1.0) NA 97.81 117.42 Total 42 34 (33.7) 9.1 (4.8) 151.18 181.49 NTRK IHC 41 41 (40.6) NA 97.81 117.42 RET FISH 38 34 (33.7) 10.9 (7.4) 134.48 161.44 HER2 IHC 12 12 (11.9) NA 97.81 117.42 DISH 7 7 (6.9) NA 436.26* 523.73 Sanger sequencing 3 2 (2.0) 10.3 (6.4) 71.19 85.46 FISH 1 1 (1.0) 10.9 134.48 161.44 Total 23 14 (13.9) 10.6 (3.6) 178.51 214.30 FGR1 FISH 5 5 (5.0) 17.8 (4.6) 134.48 161.44 EGFR FISH 3 2 (2.0) 9.2 (5.9) 134.48 161.44 Sanger sequencing 2 1 (1.0) NA 71.19 85.46 Total 5 3 (3.0) 9.2 (5.9) 115.01 138.07 EGFR T790M HRM sequencing 4 4 (4.0) 5.9 (2.0) 97.62 117.19 NRAS Sanger sequencing 1 1 (1.0) 55 (0.0) 60.58 72.73 HRM sequencing 1 1 (1.0 7.8 (0.0) 74.56 89.51 Total 2 2 (2.0) 31.4 (23.6) 67.57 81.12 NRAS exon 4 Sanger sequencing 2 2 (2.0) 9.2 (2.4) 60.58 72.73 TP53 Sanger sequencing 2 2 (2.0) 9.2 (0.0) 65.40 78.51 KRAS HRM sequencing 1 1 (1.0) 8.2 (0.0) 97.62 117.19 Sanger sequencing 1 1 (1.0) 6.8 (0.0) 67.33 80.83 Total 2 2 (2.0) 7.5 (0.7) 82.47 99.01 The table includes only biomarkers that were tested more than once.

    Multiplex Assay:

    Article Title: Real-World Utilization of Biomarker Testing for Patients with Advanced Non-Small Cell Lung Cancer in a Tertiary Referral Center and Referring Hospitals.
    Article Snippet: In some patients, the same test was Table 2 Descriptives of Biomarker Tests Conducted at the CCC Biomarker Test technique or platform Absolute frequency Unique patients tested, n (%) Turnaround time, median (IQR), days Cost, EUR Cost, USD MET exon 14 deletion RT-PCR 85 78 (77.2) 8.1 (4.1) 275.24 330.43 EGFR, HER2 Multiplex fragment analysis 77 73 (72.3) 8.3 (5.0) 436.26* 523.73 PD-L1 IHC 70 70 (69.3) NA 93.74 112.53 Assay TSACP MiSeq (Illumina, San Diego, CA)y 44 41 (40.6) 11.8 (3.8) 258.96 310.88 Path version 2Dz 23 17 (16.8) 86.9 (100) 993.67x 1192.90 Archer FusionPlex MiSeq (Illumina){ 2 2 (2.0) 9.1 (9.1) 993.67x 1192.90 Total 69 54 (53.5) 12.8 (9.2) 417.57 501.23 ALK IHC 54 54 (53.5) NA 101.88 122.31 FISH 5 3 (3.0) 7.7 (4.8) 134.48 161.44 Total 59 55 (54.5) 7.7 (4.8) 102.16 122.64 ROS1 IHC 50 50 (49.5) NA 101.88 122.31 FISH 8 6 (5.9) 9.9 (3.1) 134.48 161.44 Total 58 51 (50.5) 9.9 (3.1) 102.69 123.28 Hotspot panel Sequenom MassARRAY 51 46 (45.5) 7.8 (3.2) 436.26* 523.73 MET FISH 33 29 (28.7) 9.1 (4.8) 134.48 161.44 DISH 8 8 (7.9) NA 436.26* 523.73 IHC 1 1 (1.0) NA 97.81 117.42 Total 42 34 (33.7) 9.1 (4.8) 151.18 181.49 NTRK IHC 41 41 (40.6) NA 97.81 117.42 RET FISH 38 34 (33.7) 10.9 (7.4) 134.48 161.44 HER2 IHC 12 12 (11.9) NA 97.81 117.42 DISH 7 7 (6.9) NA 436.26* 523.73 Sanger sequencing 3 2 (2.0) 10.3 (6.4) 71.19 85.46 FISH 1 1 (1.0) 10.9 134.48 161.44 Total 23 14 (13.9) 10.6 (3.6) 178.51 214.30 FGR1 FISH 5 5 (5.0) 17.8 (4.6) 134.48 161.44 EGFR FISH 3 2 (2.0) 9.2 (5.9) 134.48 161.44 Sanger sequencing 2 1 (1.0) NA 71.19 85.46 Total 5 3 (3.0) 9.2 (5.9) 115.01 138.07 EGFR T790M HRM sequencing 4 4 (4.0) 5.9 (2.0) 97.62 117.19 NRAS Sanger sequencing 1 1 (1.0) 55 (0.0) 60.58 72.73 HRM sequencing 1 1 (1.0 7.8 (0.0) 74.56 89.51 Total 2 2 (2.0) 31.4 (23.6) 67.57 81.12 NRAS exon 4 Sanger sequencing 2 2 (2.0) 9.2 (2.4) 60.58 72.73 TP53 Sanger sequencing 2 2 (2.0) 9.2 (0.0) 65.40 78.51 KRAS HRM sequencing 1 1 (1.0) 8.2 (0.0) 97.62 117.19 Sanger sequencing 1 1 (1.0) 6.8 (0.0) 67.33 80.83 Total 2 2 (2.0) 7.5 (0.7) 82.47 99.01 The table includes only biomarkers that were tested more than once.

    Immunohistochemistry:

    Article Title: Real-World Utilization of Biomarker Testing for Patients with Advanced Non-Small Cell Lung Cancer in a Tertiary Referral Center and Referring Hospitals.
    Article Snippet: In some patients, the same test was Table 2 Descriptives of Biomarker Tests Conducted at the CCC Biomarker Test technique or platform Absolute frequency Unique patients tested, n (%) Turnaround time, median (IQR), days Cost, EUR Cost, USD MET exon 14 deletion RT-PCR 85 78 (77.2) 8.1 (4.1) 275.24 330.43 EGFR, HER2 Multiplex fragment analysis 77 73 (72.3) 8.3 (5.0) 436.26* 523.73 PD-L1 IHC 70 70 (69.3) NA 93.74 112.53 Assay TSACP MiSeq (Illumina, San Diego, CA)y 44 41 (40.6) 11.8 (3.8) 258.96 310.88 Path version 2Dz 23 17 (16.8) 86.9 (100) 993.67x 1192.90 Archer FusionPlex MiSeq (Illumina){ 2 2 (2.0) 9.1 (9.1) 993.67x 1192.90 Total 69 54 (53.5) 12.8 (9.2) 417.57 501.23 ALK IHC 54 54 (53.5) NA 101.88 122.31 FISH 5 3 (3.0) 7.7 (4.8) 134.48 161.44 Total 59 55 (54.5) 7.7 (4.8) 102.16 122.64 ROS1 IHC 50 50 (49.5) NA 101.88 122.31 FISH 8 6 (5.9) 9.9 (3.1) 134.48 161.44 Total 58 51 (50.5) 9.9 (3.1) 102.69 123.28 Hotspot panel Sequenom MassARRAY 51 46 (45.5) 7.8 (3.2) 436.26* 523.73 MET FISH 33 29 (28.7) 9.1 (4.8) 134.48 161.44 DISH 8 8 (7.9) NA 436.26* 523.73 IHC 1 1 (1.0) NA 97.81 117.42 Total 42 34 (33.7) 9.1 (4.8) 151.18 181.49 NTRK IHC 41 41 (40.6) NA 97.81 117.42 RET FISH 38 34 (33.7) 10.9 (7.4) 134.48 161.44 HER2 IHC 12 12 (11.9) NA 97.81 117.42 DISH 7 7 (6.9) NA 436.26* 523.73 Sanger sequencing 3 2 (2.0) 10.3 (6.4) 71.19 85.46 FISH 1 1 (1.0) 10.9 134.48 161.44 Total 23 14 (13.9) 10.6 (3.6) 178.51 214.30 FGR1 FISH 5 5 (5.0) 17.8 (4.6) 134.48 161.44 EGFR FISH 3 2 (2.0) 9.2 (5.9) 134.48 161.44 Sanger sequencing 2 1 (1.0) NA 71.19 85.46 Total 5 3 (3.0) 9.2 (5.9) 115.01 138.07 EGFR T790M HRM sequencing 4 4 (4.0) 5.9 (2.0) 97.62 117.19 NRAS Sanger sequencing 1 1 (1.0) 55 (0.0) 60.58 72.73 HRM sequencing 1 1 (1.0 7.8 (0.0) 74.56 89.51 Total 2 2 (2.0) 31.4 (23.6) 67.57 81.12 NRAS exon 4 Sanger sequencing 2 2 (2.0) 9.2 (2.4) 60.58 72.73 TP53 Sanger sequencing 2 2 (2.0) 9.2 (0.0) 65.40 78.51 KRAS HRM sequencing 1 1 (1.0) 8.2 (0.0) 97.62 117.19 Sanger sequencing 1 1 (1.0) 6.8 (0.0) 67.33 80.83 Total 2 2 (2.0) 7.5 (0.7) 82.47 99.01 The table includes only biomarkers that were tested more than once.

    Fluorescence In Situ Hybridization:

    Article Title: Real-World Utilization of Biomarker Testing for Patients with Advanced Non-Small Cell Lung Cancer in a Tertiary Referral Center and Referring Hospitals.
    Article Snippet: In some patients, the same test was Table 2 Descriptives of Biomarker Tests Conducted at the CCC Biomarker Test technique or platform Absolute frequency Unique patients tested, n (%) Turnaround time, median (IQR), days Cost, EUR Cost, USD MET exon 14 deletion RT-PCR 85 78 (77.2) 8.1 (4.1) 275.24 330.43 EGFR, HER2 Multiplex fragment analysis 77 73 (72.3) 8.3 (5.0) 436.26* 523.73 PD-L1 IHC 70 70 (69.3) NA 93.74 112.53 Assay TSACP MiSeq (Illumina, San Diego, CA)y 44 41 (40.6) 11.8 (3.8) 258.96 310.88 Path version 2Dz 23 17 (16.8) 86.9 (100) 993.67x 1192.90 Archer FusionPlex MiSeq (Illumina){ 2 2 (2.0) 9.1 (9.1) 993.67x 1192.90 Total 69 54 (53.5) 12.8 (9.2) 417.57 501.23 ALK IHC 54 54 (53.5) NA 101.88 122.31 FISH 5 3 (3.0) 7.7 (4.8) 134.48 161.44 Total 59 55 (54.5) 7.7 (4.8) 102.16 122.64 ROS1 IHC 50 50 (49.5) NA 101.88 122.31 FISH 8 6 (5.9) 9.9 (3.1) 134.48 161.44 Total 58 51 (50.5) 9.9 (3.1) 102.69 123.28 Hotspot panel Sequenom MassARRAY 51 46 (45.5) 7.8 (3.2) 436.26* 523.73 MET FISH 33 29 (28.7) 9.1 (4.8) 134.48 161.44 DISH 8 8 (7.9) NA 436.26* 523.73 IHC 1 1 (1.0) NA 97.81 117.42 Total 42 34 (33.7) 9.1 (4.8) 151.18 181.49 NTRK IHC 41 41 (40.6) NA 97.81 117.42 RET FISH 38 34 (33.7) 10.9 (7.4) 134.48 161.44 HER2 IHC 12 12 (11.9) NA 97.81 117.42 DISH 7 7 (6.9) NA 436.26* 523.73 Sanger sequencing 3 2 (2.0) 10.3 (6.4) 71.19 85.46 FISH 1 1 (1.0) 10.9 134.48 161.44 Total 23 14 (13.9) 10.6 (3.6) 178.51 214.30 FGR1 FISH 5 5 (5.0) 17.8 (4.6) 134.48 161.44 EGFR FISH 3 2 (2.0) 9.2 (5.9) 134.48 161.44 Sanger sequencing 2 1 (1.0) NA 71.19 85.46 Total 5 3 (3.0) 9.2 (5.9) 115.01 138.07 EGFR T790M HRM sequencing 4 4 (4.0) 5.9 (2.0) 97.62 117.19 NRAS Sanger sequencing 1 1 (1.0) 55 (0.0) 60.58 72.73 HRM sequencing 1 1 (1.0 7.8 (0.0) 74.56 89.51 Total 2 2 (2.0) 31.4 (23.6) 67.57 81.12 NRAS exon 4 Sanger sequencing 2 2 (2.0) 9.2 (2.4) 60.58 72.73 TP53 Sanger sequencing 2 2 (2.0) 9.2 (0.0) 65.40 78.51 KRAS HRM sequencing 1 1 (1.0) 8.2 (0.0) 97.62 117.19 Sanger sequencing 1 1 (1.0) 6.8 (0.0) 67.33 80.83 Total 2 2 (2.0) 7.5 (0.7) 82.47 99.01 The table includes only biomarkers that were tested more than once.

    Sequencing:

    Article Title: Real-World Utilization of Biomarker Testing for Patients with Advanced Non-Small Cell Lung Cancer in a Tertiary Referral Center and Referring Hospitals.
    Article Snippet: In some patients, the same test was Table 2 Descriptives of Biomarker Tests Conducted at the CCC Biomarker Test technique or platform Absolute frequency Unique patients tested, n (%) Turnaround time, median (IQR), days Cost, EUR Cost, USD MET exon 14 deletion RT-PCR 85 78 (77.2) 8.1 (4.1) 275.24 330.43 EGFR, HER2 Multiplex fragment analysis 77 73 (72.3) 8.3 (5.0) 436.26* 523.73 PD-L1 IHC 70 70 (69.3) NA 93.74 112.53 Assay TSACP MiSeq (Illumina, San Diego, CA)y 44 41 (40.6) 11.8 (3.8) 258.96 310.88 Path version 2Dz 23 17 (16.8) 86.9 (100) 993.67x 1192.90 Archer FusionPlex MiSeq (Illumina){ 2 2 (2.0) 9.1 (9.1) 993.67x 1192.90 Total 69 54 (53.5) 12.8 (9.2) 417.57 501.23 ALK IHC 54 54 (53.5) NA 101.88 122.31 FISH 5 3 (3.0) 7.7 (4.8) 134.48 161.44 Total 59 55 (54.5) 7.7 (4.8) 102.16 122.64 ROS1 IHC 50 50 (49.5) NA 101.88 122.31 FISH 8 6 (5.9) 9.9 (3.1) 134.48 161.44 Total 58 51 (50.5) 9.9 (3.1) 102.69 123.28 Hotspot panel Sequenom MassARRAY 51 46 (45.5) 7.8 (3.2) 436.26* 523.73 MET FISH 33 29 (28.7) 9.1 (4.8) 134.48 161.44 DISH 8 8 (7.9) NA 436.26* 523.73 IHC 1 1 (1.0) NA 97.81 117.42 Total 42 34 (33.7) 9.1 (4.8) 151.18 181.49 NTRK IHC 41 41 (40.6) NA 97.81 117.42 RET FISH 38 34 (33.7) 10.9 (7.4) 134.48 161.44 HER2 IHC 12 12 (11.9) NA 97.81 117.42 DISH 7 7 (6.9) NA 436.26* 523.73 Sanger sequencing 3 2 (2.0) 10.3 (6.4) 71.19 85.46 FISH 1 1 (1.0) 10.9 134.48 161.44 Total 23 14 (13.9) 10.6 (3.6) 178.51 214.30 FGR1 FISH 5 5 (5.0) 17.8 (4.6) 134.48 161.44 EGFR FISH 3 2 (2.0) 9.2 (5.9) 134.48 161.44 Sanger sequencing 2 1 (1.0) NA 71.19 85.46 Total 5 3 (3.0) 9.2 (5.9) 115.01 138.07 EGFR T790M HRM sequencing 4 4 (4.0) 5.9 (2.0) 97.62 117.19 NRAS Sanger sequencing 1 1 (1.0) 55 (0.0) 60.58 72.73 HRM sequencing 1 1 (1.0 7.8 (0.0) 74.56 89.51 Total 2 2 (2.0) 31.4 (23.6) 67.57 81.12 NRAS exon 4 Sanger sequencing 2 2 (2.0) 9.2 (2.4) 60.58 72.73 TP53 Sanger sequencing 2 2 (2.0) 9.2 (0.0) 65.40 78.51 KRAS HRM sequencing 1 1 (1.0) 8.2 (0.0) 97.62 117.19 Sanger sequencing 1 1 (1.0) 6.8 (0.0) 67.33 80.83 Total 2 2 (2.0) 7.5 (0.7) 82.47 99.01 The table includes only biomarkers that were tested more than once.



    Similar Products

    hotspot panel sequenom massarray  (Sequenom)
    90
    Sequenom hotspot panel sequenom massarray
    Hotspot Panel Sequenom Massarray, supplied by Sequenom, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/hotspot+panel+sequenom+massarray/hotspot+panel+sequenom+massarray/pm33493663-79-161-163
    Average 90 stars, based on 1 article reviews
    hotspot panel sequenom massarray - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier

    Image Search Results